$NUWEJun 24, 2026, 3:10 PMAI processed
Nuwellis names Mike McCormick CEO; plans pediatric expansion to ≥5 kg and adds Rendiatech kidney-monitoring tech
AI Summary
Nuwellis appointed Mike McCormick as CEO effective June 30 and issued a shareholder letter outlining priorities: expand commercial momentum in pediatric/critical care, pursue FDA engagement to broaden Aquadex use down to patients ≥5 kg using existing clinical and real‑world data, and integrate the recently acquired Rendiatech kidney‑function monitoring into its ICU portfolio. The company reported Q1 results showing 26% YoY revenue growth and a 70.1% gross margin, said its capital position is strengthened, and reiterated targets of consistent double‑digit revenue growth, margin expansion and reduced cash burn.
Positives
- Q1: 26% year‑over‑year revenue growth and gross margin improvement to 70.1% (14 percentage points YoY)
- Engaged FDA on submission strategy to expand Aquadex indication to children ≥5 kg using existing clinical experience and real‑world evidence
- Acquired Rendiatech to add automated kidney‑function monitoring, expanding ICU product capabilities and cross‑sell opportunities
Negatives
- Revenue is concentrated: ~75% generated from pediatric and critical care categories (customer concentration risk)
- Company notes execution and funding risks in forward‑looking statements, including potential inability to raise sufficient funds for planned operations